Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta-regression analysis of randomized controlled trials.

Chi-Jung HuangWei-Ting WangShih-Hsien SungChen-Huan ChenGregory Y H LipBabangida S ChoriChern-En Chiang

Published in: Diabetes, obesity & metabolism (2018)

Compared with placebo, newer T2D agents with less hypoglycaemic hazard significantly reduced the risk of MACE. The MACE reduction appears to be associated with HbA1c reduction in a linear relationship.

Keyphrases

blood glucose
type diabetes
clinical trial
metabolic syndrome
adipose tissue
skeletal muscle
wound healing
open label